Subacute Thyroiditis Associated with COVID-19 Infection: Two Case Reports

COVID-19 Enfeksiyonu ile İlişkili Subakut Tiroidit: İki Olgu Sunumu

Mustafa ÜNÜBOL, Zehra ERDEM, Gökhan ÇOLAK*, Mustafa Gökhan ÜNSAL**, Engin GÜNEY

Division of Endocrinology and Metabolism, Aydın Adnan Menderes University Faculty of Medicine, Aydın, TURKEY
*Department of Internal Medicine, Aydın Adnan Menderes University Faculty of Medicine, Aydın, TURKEY
**Department of General Surgery, Aydın Adnan Menderes University Faculty of Medicine, Aydın, TURKEY

Abstract
Subacute thyroiditis (SAT) is granulomatous thyroiditis of the thyroid gland that usually occurs after a viral infection. Coronavirus disease-2019 (COVID-19) infection has led to a pandemic that has affected the whole world since late 2019. The virus has been reported to cause different extrapulmonary clinical symptoms. Few cases in the literature have reported SAT after COVID-19 viral infection. In this article, 2 cases were diagnosed, where SAT was presented after COVID-19 infection. Using these cases, we aimed to emphasize that patients who present with pain and tenderness in the anterior neck region after COVID-19 infection may develop SAT, whose diagnosis can be missed.

Keywords: Subacute thyroiditis; COVID-19; SARS-CoV-2

Introduction
Subacute (granulomatous, de Quervain’s) thyroiditis (SAT) is defined as an inflammatory, granulomatous and painful thyroiditis and is usually developed after an upper respiratory viral infection (1). It has also been reported after many other viral infections (2). Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has lead to coronavirus disease-2019 (COVID-19) since late 2019 (3). The first case of SAT after SARS-CoV-2 infection was reported by Brancatella et al. in 2020 (4). SAT after COVID-19 infection has been reported in few literature cases until now (5). Here, we reported two cases of SAT in patients affected by COVID-19 infection.

Anahtar kelimeler: Subakut tiroidit; COVID-19; SARS-CoV-2

Address for Correspondence: Mustafa ÜNÜBOL,
Division of Endocrinology and Metabolism, Aydın Adnan Menderes University Faculty of Medicine, Aydın, TURKEY
Phone: 0534 012 24 00 E-mail: drmunubol@yahoo.com.tr

Peer review under responsibility of Turkish Journal of Endocrinology and Metabolism.

Received: 10 May 2021 Received in revised form: 22 Jun 2021 Accepted: 01 Jul 2021 Available online: 17 Aug 2021
1308-9846 / © Copyright 2021 by Society of Endocrinology and Metabolism of Turkey.
Publication and hosting by Türkije Klinikleri.
This is an open access article under the CC BY-NC-SA license (https://creativecommons.org/licenses/by-nc-sa/4.0/)
Case Reports

Case 1
A 56-year-old man with no history of thyroid disease was presented to the endocrinology clinic with severe pain and swelling on the right anterior side of his neck for two weeks, which radiated to the right ear. He had fatigue and myalgia for one week. Four weeks before the onset of symptoms, he had a fever (38°C), cough, and myalgia. The patient’s nasopharyngeal reverse transcriptase-polymerase chain reaction (RT-PCR) test revealed positivity for SARS-CoV-2 while the computed tomography scanning of his chest was normal. The patient reported that his symptoms improved after a 5-day use of oral favipiravir and paracetamol. However, four weeks after his initial symptoms, the patient was presented to us with severe anterior neck pain. The patient’s thyroid gland was painful, tender, and palpable. His blood test results showed elevated erythrocyte sedimentation rate (ESR) (78 mm/h) and C-reactive protein (CRP) (45 mg/L) but normal complete blood cell count. Thyroid function tests (TFTs) revealed a low thyroid-stimulating hormone (TSH) with normal free T3 and free T4. Anti-Tg and anti-TPO were tested negative. Thyroid Tc99m scintigraphy scan showed no uptake. Thyroid ultrasound revealed the right lobe of the thyroid gland to be heterogeneous with hypoechogenic areas, suggestive of SAT. The left lobe of the thyroid gland was focally heterogeneous, and there was no cervical lymphadenopathy. The demographic features along with clinical, laboratory, and radiographic findings of patients with SAT after COVID-19 infection are shown in Table 1. After the patient was diagnosed with SAT, he was started on 550 mg of oral naproxen sodium twice a day. His pain disappeared within two days, while the remaining symptoms were relieved within ten days. Later, the naproxen sodium treatment was continued for four weeks while the patient was being followed up as an outpatient. After the treatment, TFTs and inflammatory markers (ESR, CRP) were tested to be normal (Table 2).

Case 2
A 38-year-old woman with no history of thyroid disease was presented to the endocrinology clinic with an abnormal level of TSH. She was presented with fatigue, myalgia, back pain, and headache. Thyroid Tc99m scintigraphy scan showed no uptake. Thyroid ultrasound revealed the right lobe of the thyroid gland to be heterogeneous with hypoechogenic areas, suggestive of SAT. The left lobe of the thyroid gland was focally heterogeneous, and there was no cervical lymphadenopathy. The demographic features along with clinical, laboratory, and radiographic findings of patients with SAT after COVID-19 infection are shown in Table 1. After the patient was diagnosed with SAT, she was started on 550 mg of oral naproxen sodium twice a day. Her pain disappeared within two days, while the remaining symptoms were relieved within ten days. Later, the naproxen sodium treatment was continued for four weeks while the patient was being followed up as an outpatient. After the treatment, TFTs and inflammatory markers (ESR, CRP) were tested to be normal (Table 2).

Table 1. Demographic features along with clinical, laboratory, and radiographic findings of patients with SAT after COVID-19 infection.

| Case | Age (year) | Sex | Symptoms of COVID-19 | Symptoms of SAT | Time from diagnosis of COVID-19 (weeks) | Time from diagnosis of SAT (weeks) | Findings of Thyroid Tc99m scintigraphy | Findings of thyroid USG | Findings of Thyroid Function Tests | Findings of Thyroid Hormone Studies | Treatment |
|------|------------|-----|----------------------|----------------|----------------------------------------|-----------------------------------|--------------------------------------|------------------------|----------------------------------|-------------------------|----------------|
| 1    | 56         | M   | Mild                 | Anterior neck pain, myalgia, fatigue | 4 weeks                             | 6 weeks                           | No uptake                            | Heterogeneous thyroid, hypoechogenic areas, decreased vascularity (unilateral-right lobe) | Subclinical            | TSH Normal, free T3 Normal, free T4 Normal | Naproxen sodium (NSAID) |
| 2    | 38         | F   | Mild                 | Anterior neck pain, myalgia, fatigue, back pain, headache | 4 weeks                             | 9 weeks                           | Heterogeneous thyroid, hypoechogenic areas, decreased vascularity (bilateral) | Subclinical            | TSH Normal, free T3 Normal, free T4 Normal | Naproxen sodium (NSAID) |
pain, headache, and anterior neck pain for five weeks. Four weeks before the onset of symptoms, the patient experienced a sore throat. The patient’s nasopharyngeal RT-PCR test was positive for SARS-CoV-2. She reported that her symptoms improved after oral favipiravir treatment. Four weeks after her initial symptoms, she was presented with severe back pain and myalgia. Initially, paracetamol and myorelaxant were administered to the patient considering it as a COVID-19 related pain. Later, chest X-ray examination, thoracic tomography, and D-Dimer tests were requested by the pulmonologist, whose results were evaluated as normal. Physical therapy was applied to the patient, and she was further consulted with a neurology doctor. The diagnosis of fibromyalgia led to the administration of Duloxetine. As the patient started complaining of pain in the anterior neck region and throat while swallowing and an increase in headache, antibiotic treatment was initiated by the otolaryngologist. However, the patient’s complaints did not disappear, and she was applied to general surgery. Later, she was referred to endocrinology due to suppressed TSH levels (0.1 µIU/mL) and unresolved complaints. Physical examination of the patient revealed a painful, tender, and large thyroid gland. Also, the laboratory test results showed elevated ESR (68 mm/h) and CRP (18.4 mg/L). The patient’s thyroid function tests and whole blood count were normal. Anti-Tg and anti-TPO were negative. Bilateral and diffuse hypoechoic areas were detected during thyroid ultrasound (Table 1). SAT was diagnosed, and the patient was started with 550 mg of oral naproxen sodium twice a day, after which, the patient’s neck pain disappeared within two days. Later, naproxen sodium treatment was continued for four weeks. After the treatment, TFTs and inflammatory markers (ESR, CRP) were found to be normal (Table 2).

The patients consent was obtained for this case study.

Discussion

SAT is granulomatous thyroiditis, which usually occurs due to a viral infection in genetically predisposed patients (6). The etiopathogenesis of SAT has not been fully known (7). SAT is usually developed after a viral upper respiratory tract infection (1). Different studies have found its associations with coxsackievirus (groups A & B), echovirus, mumps, measles, influenza, cytomegalovirus, rubella, Epstein Barr, enterovirus, adenovirus, and other viruses (6,8-10). In literature, a small series of patients and clinical cases have reported the occurrence of SAT after COVID-19 infection (4,11-14). Another review of literature also evaluated 22 patients with SAT after COVID-19 infection, which showed that 81.8% of the patients were female while the average age of patients was 39. It was emphasized that SAT’s clinical symptoms emerged approximately 21±11 days after COVID-19 infection (5). In our study, the patients were a 56-year-old male and a 38-

| Case 1 | Case 2 |
|--------|--------|
| TSH (µIU/mL) | Free T4 (ng/dl) | TSH (µIU/mL) | Free T4 (ng/dl) |
| (date of diagnosis) | (4 weeks after treatment) | (date of diagnosis) | (4 weeks after treatment) |
| 0.139 | 3.8 | 0.139 | 3.8 |
| 3.0 | 1.39 | 3.0 | 1.39 |
| 0.99 | 2.30 | 0.99 | 2.30 |

Table 2. Laboratory findings of the cases before and after the treatment.
year-old female. As per our case 1, SAT clinical symptoms emerged approximately four weeks after COVID-19 infection. But, case 2 was diagnosed with SAT after five weeks of the patient’s initial symptoms. Patients may present with pain in the anterior neck region radiating to the jaw or ear region, fever, myalgia, fatigue, weakness, and signs of thyrotoxicosis (palpitations, hyperhidrosis, etc.) \(1,5\). Our cases had symptoms similar to the cases found in the literature (pain in the anterior neck region radiating to the ear, fatigue, and myalgia) and examination findings (painful, tender, and enlarged thyroid gland). Laboratory, ultrasonography, and scintigraphy findings of SAT cases reported after COVID-19 were similar to typical SAT findings \(4,11-14\). Also, laboratory findings of our cases (increased CRP and ESR, a low TSH level, diffuse heterogeneity and focal hypoechogenic areas without hypervascularization during color Doppler ultrasonography, low uptake on thyroid scintigraphy) were similar to the SAT cases after COVID-19 in the literature as well. SAT is treated with aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids. If there are symptoms of thyrotoxicosis, beta-blocker therapy can be used \(1\). Of the 22 SAT cases compiled after COVID-19, 50% used corticosteroids, 9.09% used aspirin, 4.55% used only NSAIDs, 4.55% used only beta-blockers, while 18.18% cases used blockers with other drugs, and 27.27% did not receive any treatment \(5\). In our study, both the cases recovered with NSAID therapy. In both cases, no clinical picture of symptomatic thyrotoxicosis was observed, and thus, no beta-blockers were used. Unlike the literature, our cases were treated with NSAID drugs, and complete recovery was achieved.

In the review evaluating SAT cases, 72.73% of the patients had mild COVID-19 symptoms, 13.64% had an asymptomatic disease, while 13.64% developed pneumonia \(5\). However, both our cases had mild symptoms during the COVID-19 infection. Our cases support the hypothesis that SAT may occur after a mild COVID-19 episode, which was also consistent with the literature. No significant increase was observed between SAT cases after different viral infec-

Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.
Conflict of Interest
No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions
Idea/Concept: Mustafa Ünübol, Zehra Erdemir, Engin Güney, Mustafa Gökhan Ünsal; Design: Mustafa Ünübol, Engin Güney, Mustafa Gökhan Ünsal; Control/Supervision: Mustafa Ünübol, Zehra Erdemir, Gökhan Çolak; Data Collection and/or Processing: Mustafa Ünübol, Zehra Erdemir, Gökhan Çolak, Mustafa Gökhan Ünsal, Engin Güney; Analysis and/or Interpretation: Mustafa Ünübol, Engin Güney, Gökhan Çolak; Literature Review: Mustafa Ünübol, Zehra Erdemir, Mustafa Gökhan Ünsal; Writing the Article: Mustafa Ünübol, Gökhan Çolak; Materials: Mustafa Ünübol, Zehra Erdemir.

References
1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26:1343-1421. Erratum in: Thyroid. 2017;27:1462. [Crossref][PubMed]
2. Ünübol M. Subakut granülomatöz tiroid (De Quervain Tiroidi) vakasaları. Ankara; Türkiye Klinikleri; 2020:135-139.
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. Erratum in: Lancet. 2020;395:1038. Erratum in: Lancet. 2020;395:1038. [Crossref][PubMed][PMC]
4. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after SARS-COV-2 infection. J Clin Endocrinol Metab. 2020;105:dgaa276. [Crossref][PubMed][PMC]
5. Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review. Endocrine. 2021;72:326-331. [Crossref][PubMed][PMC]
6. Sweeney LB, Stewart C, Gaitonde DY. Thyroiditis: an integrated approach. Am Fam Physician. 2014;90:389-396. [PubMed]
7. Benbassat CA, Olchovsky D, Tsetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007;30:631-635. [Crossref][PubMed][PMC]
8. Martino E, Buratti L, Bartalena L, Mariotti S, Cupini C, Aghini-Lombardi F, Pinchera A. High prevalence of subacute thyroiditis during summer season in Italy. J Endocrinol Invest. 1987;10:321-323. [Crossref][PubMed]
9. Michas G, Alevetsovitis G, Andrikou I, Tsimiklis S, Vryonis E. De Quervain thyroiditis in the course of H1N1 influenza infection. Hippokratia. 2014;18:86-87. [PubMed][PMC]
10. DesaiIoud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009;6:5. [Crossref][PubMed][PMC]
11. Ippolito S, Dentai F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest. 2020;43:1171-1172. [Crossref][PubMed][PMC]
12. Asfuroglu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. J Endocrinol Invest. 2020;43:1173-1174. [Crossref][PubMed][PMC]
13. Sohrabpour S, Heidari F, Karimi E, Ansari R, Tajdini A, Heidari F. Subacute thyroiditis in COVID-19 patients. Eur Thyroid J. 2021;9:321-323. [Crossref][PubMed][PMC]
14. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. J Clin Endocrinol Metab. 2020;105:dgaa537. [Crossref][PubMed][PMC]
15. Keskin FE, Bolu E. COVID-19 enfeksiyonu ve tiroid hastalıkları. Yılmaz MT, editör. Endokrinoloji ve COVID-19 (1. Baskı). Ankara; Türkiye Klinikleri; 2020:12-16. [Link]
16. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454. [Crossref][PubMed][PMC]
17. Riordon JF. Angiotensin-I-converting enzyme and its relatives. Genome Biol. 2003;4:225. [Crossref][PubMed][PMC]
18. Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, Villani L, Magri F, Latrofa F, Chiovato L. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44:1085-1090. [Crossref][PubMed][PMC]
19. Wei L, Sun S, Xu CH, Zhang J, Xu Y, Zhu H, Peh SC, Korteweg C, McNutt MA, Gu J. Pathology of the thyroid in severe acute respiratory syndrome. Hum Pathol. 2007;38:95-102. [Crossref][PubMed][PMC]